R01 CA61202/CA/NCI NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
1996	2
1997	1
1998	2
1999	1
2000	3
2001	4
2002	1
2003	3
2004	1
2005	1
2006	1
2007	2
2008	1
2024	0

1

Reid BJ, Blount PL, Rabinovitch PS. Reid BJ, et al. Gastrointest Endosc Clin N Am. 2003 Apr;13(2):369-97. doi: 10.1016/s1052-5157(03)00006-0. Gastrointest Endosc Clin N Am. 2003. PMID: 12916666 Review.

2

Management of dysplasia in the columnar-lined esophagus.

Levine DS. Levine DS. Gastroenterol Clin North Am. 1997 Sep;26(3):613-34. doi: 10.1016/s0889-8553(05)70318-6. Gastroenterol Clin North Am. 1997. PMID: 9309409 Review.

3

Barrett's esophagus: ordering the events that lead to cancer.

Reid BJ, Barrett MT, Galipeau PC, Sanchez CA, Neshat K, Cowan DS, Levine DS. Reid BJ, et al. Eur J Cancer Prev. 1996 Dec;5 Suppl 2:57-65. doi: 10.1097/00008469-199612002-00009. Eur J Cancer Prev. 1996. PMID: 9061296 No abstract available.

4

Optimizing endoscopic biopsy detection of early cancers in Barrett's high-grade dysplasia.

Reid BJ, Blount PL, Feng Z, Levine DS. Reid BJ, et al. Am J Gastroenterol. 2000 Nov;95(11):3089-96. doi: 10.1111/j.1572-0241.2000.03182.x. Am J Gastroenterol. 2000. PMID: 11095322

5

Predictors of progression in Barrett's esophagus III: baseline flow cytometric variables.

Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Rabinovitch PS, et al. Am J Gastroenterol. 2001 Nov;96(11):3071-83. doi: 10.1111/j.1572-0241.2001.05261.x. Am J Gastroenterol. 2001. PMID: 11721752 Free PMC article.

6

Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.

Vaughan TL, Kristal AR, Blount PL, Levine DS, Galipeau PC, Prevo LJ, Sanchez CA, Rabinovitch PS, Reid BJ. Vaughan TL, et al. Cancer Epidemiol Biomarkers Prev. 2002 Aug;11(8):745-52. Cancer Epidemiol Biomarkers Prev. 2002. PMID: 12163328

7

Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus.

Rudolph RE, Vaughan TL, Storer BE, Haggitt RC, Rabinovitch PS, Levine DS, Reid BJ. Rudolph RE, et al. Ann Intern Med. 2000 Apr 18;132(8):612-20. doi: 10.7326/0003-4819-132-8-200004180-00003. Ann Intern Med. 2000. PMID: 10766679

8

Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett's oesophagus: a prospective study.

Vaughan TL, Dong LM, Blount PL, Ayub K, Odze RD, Sanchez CA, Rabinovitch PS, Reid BJ. Vaughan TL, et al. Lancet Oncol. 2005 Dec;6(12):945-52. doi: 10.1016/S1470-2045(05)70431-9. Lancet Oncol. 2005. PMID: 16321762

9

Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's esophagus.

Srivastava A, Hornick JL, Li X, Blount PL, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD. Srivastava A, et al. Am J Gastroenterol. 2007 Mar;102(3):483-93; quiz 694. doi: 10.1111/j.1572-0241.2007.01073.x. Am J Gastroenterol. 2007. PMID: 17338734

10

Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus.

Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Maley CC, et al. Cancer Res. 2004 May 15;64(10):3414-27. doi: 10.1158/0008-5472.CAN-03-3249. Cancer Res. 2004. PMID: 15150093

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

23 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Results by year